Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.3% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price dropped 4.3% during trading on Friday . The company traded as low as $6.78 and last traded at $6.95. Approximately 5,451,801 shares traded hands during trading, a decline of 64% from the average daily volume of 15,227,077 shares. The stock had previously closed at $7.26.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on RXRX shares. KeyCorp reduced their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.75.

Recursion Pharmaceuticals Stock Performance

The company has a market cap of $2.70 billion, a price-to-earnings ratio of -4.52 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average price is $6.93 and its 200 day moving average price is $7.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the prior year, the business earned ($0.43) EPS. The business’s revenue for the quarter was up 147.6% on a year-over-year basis. On average, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84. Following the transaction, the director now owns 7,077,560 shares in the company, valued at $47,561,203.20. The trade was a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,288,380.78. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 55,341 shares of company stock worth $393,490. 15.75% of the stock is owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of RXRX. GAMMA Investing LLC lifted its position in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Recursion Pharmaceuticals by 6.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock worth $7,751,000 after buying an additional 67,464 shares in the last quarter. Franklin Resources Inc. boosted its position in Recursion Pharmaceuticals by 58.9% in the 3rd quarter. Franklin Resources Inc. now owns 18,963 shares of the company’s stock valued at $127,000 after buying an additional 7,027 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the third quarter valued at about $89,000. Finally, Geode Capital Management LLC increased its position in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after acquiring an additional 656,003 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.